Last updated: April 26, 2026
Japan Patent JP2017214378: Scope, Claims, and Landscape
What is JP2017214378 and who is the assignee?
JP2017214378 is a Japanese patent publication with the bibliographic identifier JP2017214378A (published in 2017). The record is indexed in Google Patents under that publication number. The assignee and inventor fields for this family are also shown on the Google Patents entry.
Source: Google Patents record for JP2017214378A ([1]).
What is the patent’s claimed subject matter?
The patent’s scope is limited to the subject matter defined in its independent claims, which in this record relate to a drug-related invention (composition and/or method as drafted in the application). The claim set in the JP publication is the operative document for Japan.
However, without the full claim text reproduced in the provided materials, the claim wording and claim-by-claim limitations cannot be extracted accurately here from the record alone. Per the constraints, no partial or guesswork claim construction is provided.
Source: Google Patents record for JP2017214378A ([1]).
What does the claim set cover? (independent vs dependent)
Independent claims
The JP publication contains one or more independent claims that define the invention’s minimum legal scope: typically a composition claim, a method claim, or both, with product-structure and process or use limitations.
Dependent claims
Dependent claims narrow the scope by adding specific embodiments (for example, formulation components, dosage regimen, parameter ranges, or manufacturing steps).
Claim interpretation that matters for freedom-to-operate
For an FTO or infringement assessment in Japan, the enforceable boundaries track claim language:
- Composition claims: define ingredients, amounts, and structural or functional characterizations.
- Method claims: define steps, sequence, and conditions.
- Use claims: define the therapeutic indication or patient population tied to a drug feature.
Because the actual claim language is not available in the supplied record excerpts, no limitation-level breakdown is included.
Source: Google Patents record for JP2017214378A ([1]).
How does JP2017214378 fit into the global patent family?
Family relationship
Japanese publications like JP2017214378A often correspond to earlier priority filings and may also appear as:
- PCT publications (WO numbers)
- European applications (EP)
- US applications (US)
The family mapping, including priority dates and counterpart jurisdictions, is visible on the Google Patents entry for JP2017214378A.
Source: Google Patents record for JP2017214378A ([1]).
Why family mapping affects scope
Scope and enforceability in Japan depend on:
- the priority claim (for novelty and inventive step),
- the claim amendments carried through national phase,
- and whether later family members have different claim strategies that alter the effective technical coverage.
No further family member-specific claim differences are provided here because the necessary claim texts and family documents are not included in the provided data.
Source: Google Patents record for JP2017214378A ([1]).
What is the expiration risk profile in Japan?
Term baseline
Japan patent term generally follows the standard statutory term from filing (with patent-term adjustments where applicable). Published application numbers do not directly encode grant status or adjustment details.
Practical risk factors
For an investor or R&D team, the key risk drivers are:
- whether JP2017214378A granted as a patent and the grant date,
- any divisional filings or continuations,
- and whether adjustment or extension applies.
Because the grant and legal-status details are not included in the materials here, a date-specific expiry map is not produced.
Source: Google Patents record for JP2017214378A ([1]).
How crowded is the space around JP2017214378 (Japan landscape)?
Landscape method (what matters)
A practical landscape for a specific JP publication typically groups nearby filings by:
- same drug substance / same target,
- same formulation class (e.g., oral solid, inhaled, depot),
- same therapeutic indication, and
- same key claim elements (as written).
What can be concluded with the provided dataset
Only the existence of the JP record can be confirmed from the provided materials. No competitor list, no citation-based mapping, and no claim-element overlap chart is provided because:
- the record excerpt does not include the full claim text or classification,
- and the dataset does not include the bibliographic metadata needed to build a reliable competitor matrix.
Source: Google Patents record for JP2017214378A ([1]).
What should you use to validate infringement and design-around (claim-element checklist)?
Because the claim text is not included in the provided content, the checklist below is the correct validation framework, not a substitute for actual claim review.
Composition/kit claims
- exact active ingredient identity
- salts/polymorphs/hydrates (if claimed)
- excipients and their functional definitions
- dosage form and release profile
- quantitative ranges
Method claims
- administration route
- regimen and dosing interval
- patient selection criteria (if claimed)
- step order and defined process conditions
Design-around logic
- avoid every claimed essential element in at least one independent claim
- ensure alternative embodiments do not read onto dependent claims through literal overlap
- check prosecution history for narrowing (if accessible in-file)
Source: Google Patents record for JP2017214378A ([1]).
Key Takeaways
- JP2017214378A is identifiable and indexed as a Japan drug patent publication on Google Patents. ([1])
- The patent’s enforceable scope is defined by the independent claims in the JP publication and narrowed by dependent claims, but the claim limitations are not present in the provided materials, so no claim-by-claim scope or construction is issued here. ([1])
- A complete Japan landscape (competitor mapping, citation analysis, freedom-to-operate overlap) requires claim-element and metadata extraction that is not present in the supplied record excerpts. ([1])
FAQs
1) What document is JP2017214378 in Japan?
It is a Japanese patent publication identified as JP2017214378A on Google Patents. ([1])
2) Is JP2017214378 a composition, method, or use patent?
The record indicates it is a drug-related invention under the JP publication, but the exact claim category and wording are not included in the provided materials, so no classification is asserted here. ([1])
3) How do dependent claims affect scope?
Dependent claims narrow the invention by adding specific limitations to an independent claim’s baseline subject matter. This is the controlling structure in JP claim sets. ([1])
4) How can the global family affect Japanese scope?
Global family members often track similar disclosures but can diverge in claim scope by jurisdiction and prosecution. The family structure is shown on the JP entry’s Google Patents page. ([1])
5) What is the right way to assess design-around?
Design-around must target the independent claim essentials and avoid literal reading into dependent claims. Actual element-level work requires the full claim text. ([1])
References
[1] Google Patents. “JP2017214378A.” (Accessed 2026-04-26). https://patents.google.com/patent/JP2017214378A
